MOTAWA E. EL-HOUSEINI¹, MOSTAFA S. ARAFAT², AHMED M. EL-HUSSEINY³, ISLAM M. KASEM², MAHMOUD M. KAMEL⁴, AHMED H. EL-HABASHY⁵, MEDHAT M. KHAFAGY⁶, ENAS M. RADWAN⁴, MAHA H. HELAL⁷, MONA S. ABDELLATEIF^1,*

Oncology Research, Vol.29, No.5, pp. 319-329, 2021, DOI:10.32604/or.2022.025249

Abstract Immunotherapy becomes a promising line of treatment for breast cancer (BC) however, its success rate is still limited. Methods: The study was designed to optimize the condition for producing an effective dendritic cell (DCs) based immunotherapy by using DCs and T lymphocytes together with tumor-infiltrating lymphocytes (TILs) and tumor-infiltrating DCs (TIDCs), treated with anti-PD1 and anti-CTLA4 monoclonal antibodies. This mixture of immune cells was co-cultured with autologous breast cancer cells (BCCs) isolated from 26 BC females. Results: There was a significant upregulation of CD86 and CD83 on DCs (P = 0.001 and 0.017, respectively), similarly upregulation of CD8, CD4 and… More >

Xujie Zhou^1,2,3,#, Yuting Sang^1,3,#, Jiajian Chen^1,3, Miao Mo^3,4, Jianjing Hou^1,3, Benlong Yang^1,3,*, Jiong Wu^1,2,3,*

Oncologie, Vol.24, No.3, pp. 451-469, 2022, DOI:10.32604/oncologie.2022.025226

Abstract Background: To compare the time-varying recurrence patterns of different molecular subtypes of breast cancer in the contemporary era with those in the past era. Patients and Methods: This retrospective study included 14627 consecutive invasive breast cancer patients who underwent surgery from 2008 to 2016 at Fudan University Shanghai Cancer Center. We defined the period from 2013 to 2016 as the contemporary era and that from 2008 to 2012 as the past era. Five subtypes were defined according to the immunohistochemistry results. Emphasis was made on the changing patterns of recurrence for patients with different molecular subtypes changed between the two… More >

S. Raguvaran^1,*, S. Anandamurugan², A. M. J. Md. Zubair Rahman³

Intelligent Automation & Soft Computing, Vol.35, No.2, pp. 2171-2187, 2023, DOI:10.32604/iasc.2023.028605

Abstract A customized nutrition-rich diet plan is of utmost importance for cancer patients to intake healthy and nutritious foods that help them to be strong enough to maintain their body weight and body tissues. Consuming nutrition-rich diet foods will prevent them from the side effects caused before and after treatment thereby minimizing it. This work is proposed here to provide them with an effective diet assessment plan using deep learning-based automated medical diet system. Hence, an Enhanced Long-Short Term Memory (E-LSTM) has been proposed in this paper, especially for cancer patients. This proposed method will be very useful for cancer patients… More >

Jianping Xu, Xiaoyan Liu, Sheng Yang, Yuankai Shi

Oncology Research, Vol.28, No.2, pp. 127-133, 2020, DOI:10.3727/096504019X15707896762251

Abstract Apatinib, an oral small molecular receptor tyrosine kinase inhibitor (TKI) developed first in China, exerts antiangiogenic and antineoplastic function through selectively binding and inhibiting vascular endothelial growth factor receptor 2 (VEGFR-2). In this study, we aimed to explore the efficacy and safety profile of apatinib monotherapy, or combined with chemotherapy or endothelial growth factor receptor (EGFR)-TKI in heavily pretreated non-small cell lung cancer (NSCLC) patients with brain metastases. We performed a retrospective analysis for relapsed NSCLC patients with brain metastases from our institute, who received apatinib (250 mg or 500 mg p.o. qd) monotherapy, or combination with EGFR-TKI or chemotherapy… More >

Zhiyi Peng^*1, Guohong Cao^†1, Qinming Hou^‡, Ling Li^§, Shihong Ying^*, Junhui Sun^¶, Guanhui Zhou^¶, Jian Zhou^#, Xin Zhang^*, Wenbin Ji^**, Zhihai Yu^††, Tiefeng Li^‡‡, Dedong Zhu^§, Wenhao Hu^§§, Jiansong Ji^¶¶, Haijun Du^##, Changsheng Shi^***, Xiaohua Guo^†††, Jian Fang^‡‡‡, Jun Han^§§§, Wenjiang Gu^¶¶¶, Xiaoxi Xie^###, Zhichao Sun^****, Huanhai Xu^††††, Xia Wu^‡‡‡‡, Tingyang Hu^§§§§, Jing Huang^¶¶¶¶, Hongjie Hu^‡‡‡‡, Jiaping Zheng^####, Jun Luo^####, Yutang Chen^####, Wenqiang Yu^§§§§, Guoliang Shao^####

Oncology Research, Vol.28, No.3, pp. 249-271, 2020, DOI:10.3727/096504019X15766663541105

Abstract This study aimed to investigate the efficacy, safety, and prognostic factors of drug-eluting beads transarterial chemoembolization (DEB-TACE) in treating Chinese patients with liver cancer. A total of 367 liver cancer patients from 24 medical centers were consecutively enrolled in this multiple-center, prospective cohort study, including 275 hepatocellular carcinoma (HCC) cases, 37 intrahepatic cholangiocarcinoma (ICC) cases, and 55 secondary liver cancer cases. All the patients received CalliSpheres^® DEB-TACE treatment. Treatment response, overall survival (OS), change of liver function, and adverse events (AEs) were assessed. DEB-TACE treatment achieved 19.9% complete response (CR) and 79.6% objective response rate (ORR), with mean OS of… More >

Andrea Lapucci^*†1, Gabriele Perrone^*†1, Antonello Di Paolo^‡§, Cristina Napoli^*†, Ida Landini^*†, Giandomenico Roviello^*†, Laura Calosi^¶, Antonio Giuseppe Naccarato^#, Alfredo Falcone^#, Daniele Bani^¶, Enrico Mini^*†§2, Stefania Nobili^*†§2,3

Oncology Research, Vol.28, No.6, pp. 631-644, 2020, DOI:10.3727/096504020X16056983169118

Abstract The benefit of adjuvant chemotherapy in the early stages of colorectal cancer (CRC) is still disappointing and the prediction of treatment outcome quite difficult. Recently, through a transcriptomic approach, we evidenced a role of PNN and KCNQ1OT1 gene expression in predicting response to fluoropyrimidine-based adjuvant chemotherapy in stage III CRC patients. Thus, the aim of this study was to validate in an independent cohort of stages II–III CRC patients our previous findings. PNN and KCNQ1OT1 mRNA expression levels were evaluated in 74 formalin-fixed paraffin-embedded tumor and matched normal mucosa samples obtained by stages II–III CRC patients treated with fluoropyrimidine-based adjuvant… More >

Tsung-Kun Chang^*†, Tzu-Chieh Yin^‡§, Wei-Chih Su^*†, Hsiang-Lin Tsai^*¶, Ching-Wen Huang^*¶, Yen-Cheng Chen^*, Ching-Chun Li^*, Po-Jung Chen^*, Cheng-Jen Ma^*§, Kuo-Hsiang Chuang^#, Tian-Lu Cheng^**, Jaw-Yuan Wang^{*†¶††‡‡§§}

Oncology Research, Vol.28, No.7-8, pp. 801-809, 2020, DOI:10.3727/096504021X16218531628569

Abstract Irinotecan, a topoisomerase inhibitor, is a common cytotoxic agent prescribed for metastatic colorectal cancer (mCRC) patients. Diarrhea is the most common adverse event (AE). The underlying mechanism of irinotecaninduced diarrhea is intestinal mucosal damage caused by SN-38 (active metabolite of irinotecan) hydrolyzed from SN-38G (inactive metabolite) by bacterial -glucuronidase ( G). According to an animal study, silymarin reduces the activity of bacterial G without impairing antitumor efficacy. We conducted a prospective openlabel pilot study to evaluate the effect of silymarin as supplementation in reducing toxicities of mCRC patients undergoing irinotecan-based chemotherapy. We enrolled and randomized 70 mCRC patients receiving first-line… More >

Hsiang-Lin Tsai^*†, Yen-Cheng Chen^*‡, Tzu-Chieh Yin^*§¶, Wei-Chih Su^*‡, Po-Jung Chen^*,Tsung-Kun Chang^*†, Ching-Chun Li^*, Ching-Wen Huang^*†, Jaw-Yuan Wang^{*†‡#**††‡‡}

Oncology Research, Vol.29, No.1, pp. 47-61, 2021, DOI:10.3727/096504022X16451187313084

Abstract Uridine diphosphate glucuronosyltransferase 1A1 (UGT1A1) polymorphism plays a crucial role in the increased susceptibility and toxicity of patients to irinotecan. This retrospective, observational study compared the clinical outcomes and adverse events (AEs) in RAS wild-type metastatic colorectal cancer (mCRC) patients treated with cetuximab or bevacizumab plus FOLFIRI with UGT1A1 genotyping and irinotecan dose escalation as the first-line therapy. In total, 173 patients with mCRC with RAS wild-type were enrolled. Among them, 98 patients were treated with cetuximab, whereas 75 patients were treated with bevacizumab. All patients received irinotecan dose escalation based on UGT1A1 genotyping. We compared the progression-free survival (PFS),… More >

Yicheng Xie^1,*, Jinyue Xia²

Journal of Intelligent Medicine and Healthcare, Vol.1, No.1, pp. 43-54, 2022, DOI:10.32604/jimh.2022.032405

Abstract Lung cancer is now the most common type of cancer worldwide, with high levels of morbidity and mortality. The cost of treatment and emotional stress put a high burden on families and society. This paper aims to collect relevant information and provide predictive analysis for the prognosis of patients with lung cancer. Using the public data of SEER database and the method of machine learning, a model is constructed to predict the five-year survival of patients with lung cancer. The re-coding method is used for data processing, the eigenvalues are re-coded to adapt to the construction of the model, and… More >

Delphine Déniel^1,2,*, Fabienne Le Goc-Le Sager¹, Paul Touchard³, Véronique Marty⁴, Laurence Hasle⁵, Véronique Jestin Le Tallec⁶, Monique Jegaden⁷, Annaïk Pestel⁸, Virginie Jannou⁵, Sophie Pentecôte⁹, Laurence Guen^1,2, Christophe Perrin^1,10, Sandrine Estivin^1,3

Oncologie, Vol.23, No.4, pp. 453-461, 2021, DOI:10.32604/oncologie.2021.019964

Abstract Context: Since January 2021, vaccination for COVID-19 has been made possible in France for people aged 75 and over. Patients suffering from a cancer disease are part of a group at risk to develop severe complications to COVID-19. Method: The « Unité de coordination en Onco-Gériatrie région Bretagne » (the Brittany This work is licensed under a Creative Commons Attribution 4.0 International License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. Coordinating Unit in Onco-Geriatrics) has wished to set up an inquest about the acceptability and the tolerance to COVID-19 vaccination… More >